CommercialAdministrativeLow impact
Policy Criteria Changes
Arkansas Blue Cross Blue Shield·AR · Neurology, Oncology, Hematology·Medical Policy
Effective date
Nov 15, 2025
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross is reorganizing spinal muscular atrophy treatment policies by splitting one policy into three separate policies for different drugs, and adding new safety guidelines for Ublituximab and Caplacizumab treatments. All changes are administrative reorganizations with no impact on coverage or billing requirements.
Action Required
By November 15, 2025: Update prior authorization reference materials to use new policy numbers - Policy 2025026 for Zolgensma and Policy 2025027 for Evrysdi instead of the old combined Policy 2019011. Inform providers that prescribing Briumvi requires ensuring no active serious infections including Hepatitis B, and Cablivi requires monitoring for severe infusion reactions or hemorrhage.